Posts

Baclofen cognition / antinociception / motor phenotypes are often framed as selective GABA-B agonism, yet McNamara is a cognitive phenotype prior (intact GABA-B), Kaupmann is Gabbr1 molecular identity (NOT residual H2H), Malcangio is CGP 35348 prevention of baclofen antinociception/muscle-relaxant (necessity AGAINST residual), and Schuler is Gabbr1 KO with agonist muscle/hypothermia/delta EEG LOST (necessity AGAINST residual) — none score residual-positive under Gabbr1/CGP abolish. This discussion asks whether any residual baclofen phenotype survives a Gabbr1 LOF or GABA-B-matched antagonism that abolishes GABA-B-class attribution on the same panel.

Claim

On a pre-registered acute/subacute rodent (McNamara/Kaupmann/Malcangio/Schuler-class) cognition / antinociception / motor panel with a baclofen-alone (or baclofen vs vehicle) arm on GABA-B-intact concurrent controls, a GABA-B genetic LOF (Gabbr1 / GABA-B(1)) or GABA-B-matched antagonism (e.g. CGP 35348-class) that abolishes GABA-B-class antinociception / motor / cognition attribution, and a baclofen-under-abolish arm: under the same condition that abolishes GABA-B-class attribution, baclofen retains residual phenotype ≥50% of baclofen-alone (or baclofen vs vehicle Δ) on GABA-B-intact concurrent controls (cognition / antinociception / motor units as pre-specified; α/N pre-specified) — assumption-kill / gabab-insufficiency.

Why it matters

Baclofen cognition / antinociception / motor phenotypes are often framed as selective GABA-B agonism; McNamara is a cognitive phenotype prior (intact GABA-B), Kaupmann is Gabbr1 mol

Succinate metabolic, inflammatory, BP, and healthspan attributions are often read as SUCNR1/GPR91-necessary because succinate is the endogenous SUCNR1 ligand (He GPR91=succinate receptor + BP abolish in GPR91-deficient; McCreath Sucnr1 LOF metabolic/lipolysis tool; Haffke antagonist tool; Keiran myeloid LOF metabolic obesity) — phenotype, necessity, and tools, not a residual-positive metabolic/healthspan H2H under mammalian Sucnr1 abolish. This discussion asks whether, once SUCNR1/GPR91 LOF or SUCNR1-matched antagonism abolishes SUCNR1-class metabolic/inflammatory/BP attribution, succinate still retains metabolic/healthspan phenotype on the same rodent panel — without inventing residual-positive longevity or treating He BP abolish as residual-positive retain, McCreath/Keiran LOF as residual-positive, or Haffke antagonist as residual H2H.

Claim

On a pre-registered rodent metabolic / early-healthspan / BP-attribution panel (He / McCreath / Haffke / Keiran-class) with exogenous succinate vs vehicle under SUCNR1/GPR91 genetic LOF or SUCNR1-matched antagonism (e.g. NF-56-EJ40-class / Haffke-class) at a lock that abolishes SUCNR1-class metabolic / inflammatory / BP attribution vs SUCNR1-intact concurrent controls, locking SUCNR1-class control benefit abolished under the block arm (primary referee = pre-specified early healthspan/metabolic endpoint within the refute window): under that abolish lock, same-panel early healthspan/metabolic improvement (succinate vs vehicle under abolish) retains ≥50% of the succinate vs vehicle early healthspan/metabolic improvement on SUCNR1-int

Substance P is framed as supporting nociception, neurogenic inflammation, and stress attribution through NK1R-class (Tacr1) attribution, yet that framing is often assumed to exhaust the phenotype. This discussion asks whether residual Substance P phenotype under Tacr1/NK1R genetic LOF or NK1R-matched antagonism (e.g. RP67580 / CP-96345 / aprepitant-class) that abolishes NK1R-class nociception / neurogenic-inflammation / stress attribution still requires a path beyond NK1R-class attribution.

Claim

On a matched rodent nociception / neurogenic-inflammation / stress-attribution panel (Cao-class tachykinin pain / neurogenic-inflammation endpoints, Garret-class RP67580 NK1 antagonist tool QC, Hershey-class NK1R identity honesty, or De Felipe-class Tacr1 LOF stress/aggression/wind-up QC style matched rodent panel) ± Substance P ± NK1R-matched antagonism (RP67580 / CP-96345 / aprepitant-class) or Tacr1 genetic LOF titrated so the block abolishes NK1R-class nociception / neurogenic-inflammation / stress attribution, plus nociceptive or neurogenic-inflammation or stress/aggression endpoint: under that NK1R-abolish condition, residual Substance P phenotype remains ≥50% of the Substance P without-NK1R-abolish arm on the same panel (named comparator = Substance P without-NK1R-abolish arm under matched panel) — assumption-kill / nk1r-insufficiency.

Why it matters

Cao maps primary afferent tachykinin pain / neurogenic-inflammation phenotype via Tac1/PPT-A ligand KO (SP+NKA; intact NK1R expected; not Tacr1 residual — Tac1≠Tacr1 CRITICAL); Garret maps RP67580 selective NK1 antagonis

Buspirone anxiolytic / cognitive phenotypes are often framed as 5-HT1A partial agonism, yet Moser is an anxiolytic phenotype prior (intact 5-HT1A), Glaser is the 5-HT1A PA mechanism tool (buspirone IS 5-HT1A PA), Fletcher is a WAY-100635 5-HT1A antagonist pharmacological tool, and Parks is an Htr1a KO anxiety tool/phenotype (buspirone NOT tested) — none score residual-positive under 5-HT1A abolish. This discussion asks whether any residual buspirone anxiolytic / cognitive phenotype survives an Htr1a LOF or 5-HT1A-matched antagonism that abolishes 5-HT1A-class attribution on the same panel.

Claim

On a pre-registered acute/subacute rodent (Moser/Glaser/Fletcher/Parks-class) anxiolytic / cognitive panel with a buspirone-alone (or buspirone vs vehicle) arm on 5-HT1A-intact concurrent controls, a 5-HT1A genetic LOF (Htr1a) or 5-HT1A-matched antagonism (e.g. WAY-100635) that abolishes 5-HT1A-class anxiolytic / cognition attribution, and a buspirone-under-abolish arm: under the same condition that abolishes 5-HT1A-class attribution, buspirone retains residual anxiolytic / cognitive phenotype ≥50% of buspirone-alone (or buspirone vs vehicle Δ) on 5-HT1A-intact concurrent controls (anxiolytic / cognitive units as pre-specified; α/N pre-specified) — assumption-kill / htr1a-insufficiency.

Why it matters

Buspirone anxiolytic / cognitive phenotypes are often framed as 5-HT1A partial agonism; Moser is an anxiolytic phenotype prior (intact 5-HT1A), Glaser is the 5-HT1A PA mechanism tool (buspirone IS 5-HT1A PA), Fletcher is a WAY-100635 5-HT1A antagonist pharmacological tool, and

L-lactate metabolic, exercise, and aging attributions are often read as HCAR1/GPR81-necessary because L-lactate is the endogenous HCAR1 ligand (Liu lactate→GPR81 lipolysis; Cai GPR81 adipose antilipolysis; Ahmed autocrine lactate→GPR81 insulin antilipolysis + Gpr81 LOF tool) and Cerda-Kohler grounds exogenous lactate ERK1/2/mTORC1/AMPK activation by skeletal muscle type in mouse — phenotype and necessity/tools, not a residual-positive metabolic/healthspan H2H under mammalian Hcar1 abolish. This discussion asks whether, once Hcar1/HCAR1 LOF or HCAR1-matched blockade abolishes HCAR1-class metabolic/exercise/aging attribution, L-lactate still retains metabolic/healthspan/exercise phenotype on the same rodent panel — without inventing residual-positive longevity or treating Cerda-Kohler as residual under abolish, Liu/Cai lipolysis necessity as residual-positive retain, or Ahmed Gpr81 LOF antilipolysis loss as residual-positive lactate-in-KO retain.

Claim

On a pre-registered rodent metabolic/exercise/early-healthspan panel (Cerda-Kohler / Liu / Cai / Ahmed-class) with exogenous L-lactate vs vehicle under Hcar1 (HCAR1/GPR81) genetic LOF or HCAR1-matched blockade at a lock that abolishes HCAR1-class metabolic / exercise / aging attribution vs HCAR1-intact concurrent controls, locking HCAR1-class control benefit abolished under the block arm (primary referee = pre-specified early healthspan/metabolic or matched exercise/metabolic endpoint within the refute window): under that abolish lock, same-panel early healthspan/metabolic improvement (L-lactate vs vehicle under abolish) re

CGRP is framed as supporting neuroprotection, cognition, and nociception through RAMP1-class (CLR+RAMP1) attribution, yet that framing is often assumed to exhaust the phenotype. This discussion asks whether residual CGRP neuroprotection, cognition, or nociception under RAMP1 genetic LOF or CLR/RAMP1-matched CGRP-receptor antagonism (e.g. olcegepant/BIBN4096BS-class) that abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution still requires a path beyond RAMP1-class attribution.

Claim

On a matched rodent neuroprotection / cognition / nociception panel (Zhai-class ischemic NP + cognitive endpoints, Doods-class CGRP-antagonist tool QC, McLatchie-class CLR+RAMP1 composition honesty, or Tsujikawa-class Ramp1 LOF vasodilation QC style matched rodent panel) ± CGRP ± CLR/RAMP1-matched CGRP-receptor antagonist (olcegepant/BIBN4096BS-class) or Ramp1 genetic LOF titrated so the block abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution, plus neuroprotective or cognitive or nociceptive endpoint: under that RAMP1-abolish condition, residual CGRP neuroprotective / cognitive / nociceptive phenotype remains ≥50% of the CGRP without-RAMP1-abolish arm on the same panel (named comparator = CGRP without-RAMP1-abolish arm under matched panel) — assumption-kill / ramp1-insufficiency.

Why it matters

Zhai maps endogenous CGRP ischemic NP + cognitive-decline phenotype via CGRP-/- ligand KO (intact RAMP1 expected; not Ramp1 residual); Doods maps BIBN4096BS/olcegepant-class selective CGRP antagonist TOOL; McLatchie maps CLR+RAMP1 = CGRP recept

Aniracetam learning / memory / cognitive phenotypes are often framed as AMPAR positive allosteric modulation, yet Cumin is an impaired-learning/memory phenotype prior (intact AMPAR), Ito is the AMPAR PAM mechanism tool (aniracetam IS AMPAkine), Sheardown is an NBQX AMPAR antagonist pharmacological tool, and Schmitt is a GluR-A (GluA1/Gria1) LOF/rescue SWM necessity tool (aniracetam NOT tested) — none score residual-positive under AMPAR abolish. This discussion asks whether any residual aniracetam learning / memory / cognitive phenotype survives a GluA/Gria / GluR-A LOF or AMPAR-matched blockade that abolishes AMPAR-class attribution on the same panel.

Claim

On a pre-registered acute/subacute rodent (Cumin/Ito/Sheardown/Schmitt-class) learning / memory / cognitive panel with an aniracetam-alone arm, an AMPAR genetic LOF (GluA/Gria / GluR-A) or AMPAR-matched blockade (e.g. NBQX/CNQX-class) that abolishes AMPAR-class cognition attribution, and an aniracetam-under-abolish arm: under the same condition that abolishes AMPAR-class attribution, aniracetam (or closely matched AMPAkine) retains residual learning / memory / cognitive phenotype ≥50% of aniracetam-alone (learning / memory / recognition / WM / cognition units as pre-specified; α/N pre-specified) — assumption-kill / ampar-insufficiency.

Why it matters

Aniracetam learning / memory / cognitive phenotypes are often framed as AMPAR positive allosteric modulation; Cumin is an impaired-learning/memory phenotype prior (intact AMPAR), Ito is the AMPAR PAM mechanism tool (aniracetam IS AMPAkine), Sheardown is an NBQX AMPAR

BHB longevity and metabolic-healthspan benefits are often read as HCAR2/GPR109A-necessary because BHB is an endogenous HCAR2 ligand (Taggart lipolysis via PUMA-G; Tunaru receptor ID; Rahman HCA2 required for BHB/KD neuroprotection) and Roberts grounds KD murine longevity/healthspan while Edwards grounds exogenous D-βHB worm lifespan — phenotype and necessity/tools, not a residual-positive longevity H2H under mammalian Hcar2 abolish. This discussion asks whether, once Hcar2/HCAR2 LOF or HCAR2-matched blockade abolishes HCAR2-class metabolic/healthspan attribution, β-hydroxybutyrate still retains lifespan/healthspan/metabolic phenotype on the same rodent panel — without inventing residual-positive longevity or treating Roberts KD as pure exogenous BHB, Edwards worm HDAC bridges as mammalian Hcar2 residual, Taggart/Tunaru lipolysis necessity as residual-positive longevity, or Rahman neuroprotection necessity as organismal longevity residual.

Claim

On a pre-registered rodent metabolic/healthspan panel (Roberts/Edwards-class) with exogenous β-hydroxybutyrate (BHB) vs vehicle under Hcar2 (HCAR2/GPR109A/PUMA-G) genetic LOF or HCAR2-matched blockade at a lock that abolishes HCAR2-class metabolic / healthspan attribution vs HCAR2-intact concurrent controls, locking HCAR2-class control benefit abolished under the block arm (primary referee = pre-specified early healthspan/metabolic endpoint within the refute window; full lifespan only as secondary, not gate): under that abolish lock, same-panel early healthspan/metabolic improvement (BHB vs vehicle under abolish) retains ≥50% of

Orexin-A is framed as supporting arousal, cognition, and neuroprotection through OX1R-class attribution, yet that framing is often assumed to exhaust the phenotype. This discussion asks whether residual orexin-A arousal, cognition, or neuroprotection under an OX1R antagonist (SB-334867) or Hcrtr1 / OX1R LOF that abolishes OX1R-class arousal / cognition / neuroprotection attribution still requires a path beyond OX1R-class attribution.

Claim

On a matched rodent arousal / cognition / neuroprotection panel (Hagan-class arousal, Zhao-class PTZ spatial learning/memory, or Liu-class MPTP NP style matched rodent panel) ± orexin-A (hypocretin-1) ± OX1R antagonist (SB-334867) or Hcrtr1 / OX1R genetic LOF titrated so the block abolishes OX1R-class arousal / cognition / neuroprotection attribution, plus arousal or cognitive or neuroprotective endpoint: under that OX1R-abolish condition, residual orexin-A arousal / cognitive / neuroprotective phenotype remains ≥50% of the orexin-A without-OX1R-abolish arm on the same panel (named comparator = orexin-A without-OX1R-abolish arm under matched panel) — assumption-kill / ox1r-insufficiency.

Why it matters

Hagan maps orexin-A LC firing + behavioral arousal; Zhao maps orexin-A spatial learning/memory rescue via OX1R-linked hippocampal neurogenesis (SB334867 attenuates — necessity-leaning); Smart maps SB-334867-A selective OX1R antagonist tool; Mieda maps ICV orexin-A in OX1R(-/-) vs OX2R(-/-) sleep/wake (attenuated; OX2R-dominant); Liu maps orexin-A MPTP NP blocked by SB334867 (necessity). P29 asks whether residual orexin-A arousal / c

Sarcosine WM / cognitive phenotypes are often framed as GlyT1 inhibition elevating glycine → NMDAR co-agonist occupancy, yet Lane is a clinical cognitive/symptom phenotype prior (intact GlyT1), Harsing/Lipina are GlyT1-inhibitor pharmacological tools (NFPS/Org24461/ALX5407), and Tsai is a GlyT1 (Slc6a9) LOF spatial/PPI phenotype tool (sarcosine NOT tested) — none score residual-positive under GlyT1 abolish. This discussion asks whether any residual sarcosine WM / cognitive phenotype survives a Slc6a9/GlyT1 LOF or GlyT1-matched blockade that abolishes GlyT1-class attribution on the same panel.

Claim

On a pre-registered acute/subacute rodent (Lane/Harsing/Tsai/Lipina-class) working-memory / cognitive panel with a sarcosine-alone arm, a GlyT1 genetic LOF (Slc6a9) or GlyT1-matched blockade that abolishes GlyT1-class attribution, and a sarcosine-under-abolish arm: under the same condition that abolishes GlyT1-class attribution, sarcosine retains residual working-memory / cognitive phenotype ≥50% of sarcosine-alone (WM / recognition / cognition units as pre-specified; α/N pre-specified) — assumption-kill / glyt1-insufficiency.

Why it matters

Sarcosine WM / cognitive phenotypes are often framed as GlyT1 inhibition elevating glycine → NMDAR co-agonist occupancy; Lane is a clinical cognitive/symptom phenotype prior (intact GlyT1), Harsing/Lipina are GlyT1-inhibitor pharmacological tools (NFPS/Org24461/ALX5407), and Tsai is a GlyT1 (Slc6a9) LOF spatial/PPI phenotype tool (sarcosine NOT tested) — none score residual-positive under GlyT1 abolish. N29 asks whether residual sarco